Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1636 1653 1654 1658
This examiner grants 100% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18541815 | BICYCLIC PEPTIDYL INHIBITOR OF TUMOR NECROSIS FACTOR-ALPHA | Non-Final OA | Ohio State Innovation Foundation |
| 18223327 | METHODS FOR TREATING GRAFT-VERSUS-HOST DISEASE USING GLP-2 AGONISTS AND ANALOGUES THEREOF | Non-Final OA | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK |
| 18460519 | FLUORINATED FIBERS FOR MULTIMODAL 1H AND 19F MRI, ULTRASOUND, FLUORESCENCE DETECTION AND CONFORMATIONAL AND TEMPERATURE DETECTION BY 19F MRS | Non-Final OA | New York University |
| 18538023 | Chimeric molecule to treat sepsis and other inflammatory conditions | Non-Final OA | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH |
| 18331331 | HIDDEN ANTIBIOTICS IN THE HUMAN PROTEOME | Non-Final OA | The Trustees of the University of Pennsylvania |
| 18276122 | Lipocalin 10 and its Truncated Protein as Therapeutic Agents for Inflammation-Induced Organ Dysfunction | Non-Final OA | University of Cincinnati |
| 18365081 | GLUCAGON-LIKE PEPTIDE-1 RECEPTOR ANTAGONISTS | Non-Final OA | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION |
| 18264157 | GLUCAGON-LIKE PEPTIDE-1 RECEPTOR ANTAGONISTS | Non-Final OA | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION |
| 18310733 | GLUCAGON DELIVERY VIA ENZYMATIC ACTUATION | Final Rejection | University of Notre Dame du Lac |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy